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Abstract.
Primary brain tumors including gliomas continue to pose significant management
challenges to clinicians. While the presentation, the pathology, and the clinical course
of these lesions is variable, the initial investigations are usually similar. Patients who
are suspected to have a brain tumor will be assessed with computed tomography
(CT) and magnetic resonance imaging (MRI). The imaging findings are used by
neurosurgeons to determine the feasibility of surgical resection and plan such an
undertaking. Imaging studies are also an indispensable tool in tracking tumor
progression or its response to treatment. As these imaging studies are non-invasive,
relatively cheap and accessible to patients, there have been many efforts over the
past two decades to increase the amount of clinically-relevant information that can
be extracted from brain imaging. Most recently, artificial intelligence (AI) techniques
have been employed to segment and characterize brain tumors, as well as to detect
progression or treatment-response. However, the clinical utility of such endeavours
remains limited due to challenges in data collection and annotation, model training,
and in the reliability of AI-generated information.
We provide a review of recent advances in addressing the above challenges.
First, to overcome the challenge of data paucity, different image imputation and
synthesis techniques along with annotation collection efforts are summarized. Next,
various training strategies are presented to meet multiple desiderata, such as model
performance, generalization ability, data privacy protection, and learning with sparse
annotations. Finally, standardized performance evaluation and model interpretability
methods have been reviewed. We believe that these technical approaches will facilitate
the development of a fully-functional AI tool in the clinical care of patients with
gliomas.
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1. Introduction
Gliomas are the most common primary tumor of the brain and spine, representing 80%
of malignant brain tumors. These lesions arise from astrocytes, oligodendrocytes or
ependymal cells and cause significant morbidity and mortality. The most aggressive
subtype, glioblastoma accounts for ∼45% of all gliomas and affected patients have
a 5-year overall survival of ∼5% [1]. These tumors exhibit an incredible degree of
inter and intra-tumoral heterogeneity which leads to variable disease presentation and
prognosis (see Figure 1 as an example). This variability was considered by Bailey
and Cushing when they initially described these lesions ninety years ago [2]. The
advent of molecular genetics and improvements in techniques like immunohistochemistry
and DNA sequencing have led to novel diagnosis classification systems that more
accurately predict disease progression and overall survival. However, the personalization
of treatment with targeted therapies remains an ongoing challenge for most gliomas.
Astrocytomas and oligodendrogliomas constitute the great majority of brain
gliomas in adults [3, 4]. These tumors were classically described and graded based upon
histopathological features. However, these diagnostic criteria led to significant inter-
observer differences and did not correspond to prognosis very well [5]. Seminal studies
by Cairncross et al. highlighted the importance of chromosome 1p/19q co-deletion
for diagnosing oligodendrogliomas [6]. Later studies found that diffuse gliomas with a
mutation in the isocitrate dehydrogenase (IDH mutated) gene had a much better overall
survival than unmutated cases (IDH wild-type) [7, 8]. These findings led scientists to
incorporate genetic characteristics in the new classification of gliomas in 2016 [3, 4].
The recent primacy of molecular genetics in diagnosing gliomas has coincided
with improving knowledge of the aberrant pathways involved in disease progression
and susceptibility to chemotherapy and radiation therapy. Consequently, clinicians
have attempted to protocolize the treatment of low- and high-grade gliomas. Stupp
et al. found that concurrent radiation and temozolamide (TMZ) improved overall
survival in patients with glioblastomas [9]. Moreover, the greatest benefits from
TMZ are seen in patients with methylguanine methyl transferase (MGMT) promoter
methylation [10, 11]. Adjuvant chemotherapy and radiation are also beneficial for
some patients with low grade gliomas. The European RTOG-9802 trial showed
that chemotherapy (procarbazine, lomustine and vincristine) after radiation increased
progression free survival (PFS) and survival [12].
In addition to studying glioma genetics which focuses on specific gene mutations,
there is growing interest in understanding these lesions at higher levels. Specifically,
genomic studies aim to understand the role of the whole genome on developing gliomas
while proteomic studies have investigated the complex interaction of various proteins
(normal and aberrant) in affected cells [13]. These fields produce large quantities of data,
and hence, rely upon novel computational methods to analyze and confirm findings. As
mentioned, brain tumor imaging techniques are non-invasive and relatively cheap. Thus,
they are integral in diagnosis, surgical planning and prognostication. The prospect of
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Figure 1. There is considerable variability in MR images obtained from patients
with gliomas. Panels A and B were obtained from patients with glioblastoma (grade
IV astrocytoma). Panels C and D from patients with a low grade astrocytoma (IDH
mutated). Panels E and F from patients with oligodendroglioma (IDH mutated and
1p/19q codeleted). All images are axial T1-weighted with gadolinium.
obtaining genomic information from brain imaging led to the establishment of a new
field: radiomics [14, 15, 16].
Glioma radiomics aim at extracting clinically relevant features from glioma imaging
as a non-invasive image biomarker, to provide information for glioma diagnosis,
treatment, or prognosis. The earlier studies used statistical methods to identify
the significant radiographic features associated with the clinical outcome. In recent
years, artificial intelligence (AI), represented by machine learning (ML) and deep
learning (DL), has enhanced glioma radiomics research. This is largely because of the
increasing volume of brain imaging data, growing computational power, and advances
in AI algorithms. Compared to traditional statistical analysis methods, machine
and deep learning are able to leverage larger amounts of clinical data with high
dimensionality. Because of this, ML and DL have been widely applied to a variety of
glioma imaging-related tasks including: (1) brain tumor segmentation: quantifying
tumor volume or segmenting the tumor region for downstream analysis tasks, and (2)
predictive tasks (classification or regression): identifying the tumor type (e.g.,
distinguishing oligodendrogliomas from astrocytomas), grade, molecular subtypes, or
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Figure 2. Growth of publications on glioma imaging and AI in the past 20 years by
PubMed searching (the search keywords can be found at: https://bit.ly/AI_in_
glioma_imaging).
genetic mutation [16, 17], and predicting patients’ treatment response, length of survival,
prognosis, or recurrence (e.g., differentiating glioma recurrence from radiation necrosis
and pseudo-progression [17]). These advances have been summarized in previous surveys
on DL in glioma imaging [18, 19, 20], ML in glioma imaging applications [21, 22], brain
tumor radiomics [23, 24] and neuroimaging biomarkers [25].
The introduction of AI to neuro-oncology imaging has been met with great
enthusiasm from clinicians. This is partially evidenced by the exponential growth in
the number of articles reporting findings. Figure 2 shows the increasing number of
publications involving ML/DL on glioma imaging in the past two decades. Despite
significant breakthroughs in this field, AI has not yet been applied to the clinical care
of patients with gliomas, due to practical challenges in data collection, model training,
and the lack of trust in performance and generalizability. To bridge the clinical utility
gap in applying AI to neuro-oncology, our review focuses on recent technical advances
addressing various challenges.
2. Challenges and technical approaches of applying AI in glioma imaging
Although machine and deep learning techniques have exhibited great potential in
analyzing glioma images, their implementation in clinical care remains an elusive goal.
Several recent reviews have broadly summarized the challenges in applying AI to clinical
medicine (some of which also apply to neuro-oncology) [26, 27, 28]. These challenges
involve the full life-cycle of developing an AI model, from 1) obtaining the training
data, to 2) training the AI models, to 3) evaluating and deploying the AI
model to clinical settings. Non-technical challenges also pose practical constrains in
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Challenge 1
Limited data & annotations
Challenge 3
Clinical deployment
Data AI model Doctor
Challenge 2
Model training
Approaches (Section 2.1)
● Clinical data collection efforts
● Data imputation and synthesis
● Obtaining data annotations
Approaches (Section 2.2)
● Model training strategies
● Handling different levels of 
annotation quality
Approaches (Section 2.3)
● Standardized performance 
evaluation and benchmarking
● Enhancing model interpretability
Figure 3. The three major challenges and technical approaches to applying AI in
glioma imaging.
developing AI techniques, including: patient data safety and privacy issue; ethical, legal
and financial barriers to developing and distributing tools that may impact a patient’s
treatment course; medical authority regulation, usability evaluation, clinical acceptance,
and medical education around the implementation of the AI-assistive tools. Next,
we review the recent advances in glioma imaging research addressing the three main
challenges. Figure 3 illustrates the relationship of the challenges and their corresponding
approaches.
2.1. Obtaining data and annotations
Machine and deep learning models require large amounts of training data to learn
from, so that their performances can be generalizable in real-world applications. One
prominent example is the ImageNet dataset (containing over 14 million images of natural
scenes) [29] that has greatly advanced AI analysis of images. However, the field of
glioma imaging is lacking such comparable large-scale, consolidated public datasets.
The prevalence of gliomas is relatively low; which, combined with the acquisition cost
and time, hinders to the collection of large datasets. Additionally, medical data is
protected by patient privacy and safety laws, making it difficult to share these images.
Furthermore, the cost of data labelling can be quite high since it requires annotation by
medical experts [25]. Figure 4 shows a comparison of several popular natural, medical
and brain imaging datasets with respect to these image acquisition factors. As shown
in the figure, natural images (ImageNet) and certain medical imaging modalities, such
as dermoscopic images (ISIC) are quick to acquire and generate small file sizes, whereas
brain imaging datasets take longer to acquire and are large in size.
Several strategies have been employed to meet the challenge of limited data and
annotations: (i) data sharing platforms and initiatives to build a collective glioma
imaging database; (ii) data imputation and synthesis techniques to address issues of
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Figure 4. The comparison of natural, medical and brain image datasets with
respect to their dataset size (y-axis), the image acquisition time (x-axis), and the
size per image (shown by the dot size). Brain imaging datasets (blue dots in the
figure): ADNI (Alzheimer’s Disease Neuroimaging Initiative) [30], ABIDE (Autism
Brain Imaging Data Exchange) [31, 32], BraTS (Brain Tumor Segmentation) [33], and
ISLES (Ischemic Stroke Lesion Segmentation) [34]. Other medical imaging datasets
(red dots): OCT (retinal optical coherence tomography images) [35], CheXpert
(chest radiographs) [36], ISIC (International Skin Image Collaboration Melanoma
Project) [37], and fastMRI (knee MRI) [38]. Natural image dataset (green dot):
ImageNet [29].
missing data and lack of sufficient data, and (iii) active learning and crowd-sourcing to
facilitate data annotation. Next, we discuss recent advances in these approaches.
2.1.1. Clinical data collection efforts
International and multi-institutional efforts have been made in the past decades
towards collecting and sharing glioma imaging data. The TCIA/TCGA (The Cancer
Imaging Archive/The Cancer Genome Atlas) service provides large publicly-available
datasets, and is a part of a collective effort by the National Institutes of Health (NIH),
the National Human Genome Research Institute (NHGRI), and multiple hospitals to
encourage the sharing of clinical, imaging (including radiographic and pathological
images) and genomic datasets for cancer research [39]. There are about 1,200 raw
brain images related to glioma in the TCIA dataset. The Brain Tumor Segmentation
(BraTS) challenge dataset [33] derived from TCIA contains 461 expert-assessed scans
(including low- and high-grade gliomas) from 19 institutions. As the largest publicly-
available glioma imaging dataset, BraTS is critical for benchmarking and has helped
advance AI applications in glioma image analysis.
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2.1.2. Data Imputation and Synthesis Methods
As mentioned, data heterogeneity and data paucity are two prominent issues in
the clinical adoption of AI in glioma imaging. As such, data imputation approaches
have been proposed to handle scenarios such as missing MRI sequences, missing voxel
intensities, low-resolution or artifact-degraded scans. Similarly, data synthesis and
augmentation techniques have been proposed to expand the available imaging data.
• Data imputation methods to deal with missing data
Several conventional machine learning methods have been proposed for MR image
imputation. Cruz et al. [40] simulated two types of missing morphological measures
in T1-weighted brain MRI scans: missing completely at random (MCAR) and
missing not at random (MNAR). They also evaluated four data imputation
techniques representative of distinct statistical approaches: substituting the missing
value with the mean of all subjects (univariate approach), k-nearest neighbors
(inferential approach), low-rank matrix approximation (analytical approach), and
random forest (statistical learning approach). The random forest-based approach
was shown to be the most accurate in recovering the gold standard results.
Jog et al. [41] proposed a random forest-based supervised image imputation
approach, which performs a non-linear regression in the feature space to predict
the intensities in various contrast-enhanced MR sequences. They evaluated their
proposed approach by synthesizing 1) T2-weighted images from skull-stripped T1-
weighted images 2) FLuid Attenuated Inversion Recovery (FLAIR) images from
T1-weighted, T2-weighted, and PD-weighted images and 3) whole head T2-weighted
images (non-skull-stripped) from T1-weighted images. Their method demonstrated
an improvement in the synthetic image quality over state-of-the-art image synthesis
algorithms, and the downstream segmentation task performed similarly for real and
imputed images. Dalca et al. [42] leveraged the shared intrinsic local fine scale
structural similarity in a collection of medical images. They used a generative
model, Gaussian mixture model (GMM), to perform brain MRI restoration in a
sparsely sampled scan, and demonstrated superior performance as compared to
state-of-the-art up-sampling super-resolution methods. They cautioned, however,
that imputed data should not be used in clinical evaluation; instead the brain mask
obtained from the restored scans can be applied to the original scans and improve
subsequent analyses.
Recently, deep learning-based approaches have been proposed for data imputation.
Chartsias et al. [43] proposed a multi-input multi-output deep model trained end-to-
end, with encoders and decoders for each MRI sequence. The latent representations
from multiple encoders were fused, and a combination of loss functions were used to
ensure that the multiple latent representations from multiple modalities are similar.
Another strategy for MRI imputation relies upon generative adversarial networks
(GANs) [44]. Welander et al. [45] compared the performances of two image-to-
image translation methods: CycleGAN [46] and UNIT [47] for the generation of
T1 and T2 MRI sequences; the generated T2 sequences had higher mean absolute
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error (MAE) and lower peak signal-to-noise ratio (PSNR) than the generated T1
sequences. Several other GAN-based methods for imputing missing MRI sequences
have been proposed [48, 49, 50, 51, 52], including CollaGAN [53] which investigated
the reconstruction of various sequences. They concluded that while T1, T2, and
T2-FLAIR can be imputed from other sequences, contrast-enhanced T1-weighted
sequences cannot be efficiently imputed.
• Data synthesis methods for data augmentation
To synthesize new images, Han et al. [54] trained two generative models, a deep
convolutional GAN (DCGAN) [55] and a Wasserstein GAN (WGAN) [56], on the
BraTS dataset to synthesize new brain MR images. To evaluate their performance,
the authors conducted a ‘visual Turing test’: doctors were asked to differentiate
real MRI from the generated images. Images generated by WGAN (classification
accuracy ranged from 53% to 64%) were mis-classified by doctors more frequently
than those generated by DCGAN (classification accuracy ranged from 54% to
70%); thus inferring that WGAN produced more visually realistic images. A
similar visual assessment was also conducted by Kazuhiro et al. [57] where five
radiologists (including two experienced neuroradiologists) attempted to classify a
random selection of 50 real and synthesized images. The classification accuracy for
the neuroradiologists were 55% and 30%; indicating that many synthesized images
were practically indistinguishable from real MRIs. Shin et al. [58] used an image-to-
image translation framework [59] to predict tumor segmentation masks from brain
MR scans and to generate brain MR scans given tumor masks. The latter was
then used to augment the segmentation training dataset. Using only the synthetic
MR images to train the model followed by fine-tuning on 10% of the real images,
the segmentation performance was superior to using only the real images. Jin et
al. [60] proposed an image-to-image translation framework for synthesizing brain
MR images from brain CT images. They leveraged a combination of adversarial
loss, dual cycle-consistent loss, and voxel-wise loss strategies to train. Models
trained using the paired data (i.e., CT and corresponding MRI scans from the same
patient) and the unpaired data (two independent collections of CT and MRI images)
together achieved higher PSNR and lower MAE compared to models trained using
only either paired or unpaired data.
2.1.3. Obtaining data annotations
Classically, MRI annotation has required the time and expertise of medical experts,
which imposes higher costs than for natural images. As such, there has been interest in
1) making the best use of expert input by annotating in an active learning setting, or
2) bypassing physician expertise and asking non-experts to annotate. We will expound
upon each of these strategies below.
Active learning (AL) is a possible workaround to training models with limited
annotated data. AL is an ML technique that reduces the annotation workload by
automatically deciding which representative samples should be annotated in order to
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train a model as quickly and efficiently as possible. Damangir et al. [61] proposed
using a cascade of support vector machines (SVMs) with an AL scheme to segment
white matter lesions from brain MR scans (a problem compounded by the dataset
being biased towards normal tissue). They observed that the proposed method yielded
accurate results while also achieving the highest sensitivity and specificity scores
amongst all methods compared. Konyushkova et al. [62] proposed leveraging the feature
and geometric uncertainties from images to increase the efficiency of AL for tumor
segmentation from brain MR images. In a later study, they modeled AL as a regression
task [63], essentially predicting the expected generalizability of a trained classifier
when annotating a specific data point. They used features extracted from a random
forest regressor trained on synthetic 2D data to perform tumor segmentation from brain
MR scans, and obtained superior results as compared to other active learning methods
(such as uncertainty sampling and active learning by learning) with considerably fewer
annotated samples.
Another popular approach of obtaining a large number of annotations quickly is
to crowd-source the annotation process; a strategy which has led to rapid advances in
computer vision [64]. The aforementioned ImageNet dataset [29] has been annotated
using a crowd-sourcing platform (Amazon Mechanical Turks). Although there may
be few medical experts within the labelling group, crowd-sourcing has been shown
to be effective in creating large quantities of annotated data; and, it is faster and
cheaper than annotation by medical experts [65]. In neuroscience research, crowd-
sourcing and gamification have helped neuroscientists to explore brain networks by
identifying neurons and their synaptic connections [66, 67]. Prior to annotating, the
crowd will be trained by learning from a few examples labelled by medical experts. The
labelling results will need to be aggregated from multiple workers to ensure the labelling
quality. To date, crowd-sourcing tasks in medical imaging have included classification,
localization and segmentation of organs or lesions [65]. Due to the image variability and
the requirement of domain knowledge, crowd-sourcing in neuroimaging, especially in
glioma research, is still in its infancy, with only a few studies in this area. For example,
to analyze diffuse intrinsic pontine glioma, 823 non-expert participants annotated 5,152
brain MR images to segment brain stem or tumor [68]. Rajchl et al. recruited 12 non-
expert to annotate super-pixels for fetal brain segmentation. The fully convolutional
network trained on crowd-sourcing annotations reached similar performance as the one
annotated by experts [69]. Keshavan et al. used crowd-sourcing to amplify expert-
labelled data for quality control of brain MRI images, and a deep learning model trained
on the amplified data reached AUC of 0.99 [70].
2.2. Training the model
Successful training requires the model to meet multiple desiderata such as satisfactory
performance, generalizability, data privacy protection, and training with sparsely
annotated data.
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2.2.1. Choosing and training models
Some practical challenges are related to model training, and we list the three most
important ones: choosing the optimal model, model generalization, and learning under
data privacy constraint.
• Choosing the optimal model
The proliferation of deep learning models has led to a considerable number of layer
designs and model architectures, loss functions, and optimizers to choose from
when designing a network. With an infinite space of possible computation graphs,
a plethora of architectures were proposed (some of the popular model architectures
include AlexNet [71], VGG16 and VGG19 [72], GoogLeNet [73], ResNet [74],
DenseNet [75], inception architectures [76, 77], U-Net [78], etc.). Moreover, even
randomly connected graphs [79], as well as strategies to perform neural architecture
search (NAS) [80, 81] have been developed in order to find the optimal model
architecture. We list the model architectures used by various works in glioma
imaging in Table 1.
• Model generalization
Models trained on images from one hospital may not be generalizable or perform
equally well on new data from another hospital or image scanner, due to
domain distribution shift and the confounding information models exploited [82].
Regularization strategies are utilized to improve model generalization and prevent
over-fitting the training dataset. These include dropout [83], early stopping [84],
data augmentation [85], or gather sufficient data from different scanners and/or
hospitals [86]. To encourage model generalization among multiple scanners, Aslani
et al. proposed to use an auxiliary network and corresponding regularization loss
term to learn the domain-specific knowledge [86]. This auxiliary network learned to
predict the category of the input scanner’s domain, thus encouraging the backbone
segmentation network to ignore domain-specific information. The experiments on
brain lesion segmentation from 56 different scanning sites showed the proposed
method had better generalization performance to data from new sites than other
baseline networks. Transfer learning [87] is also a common technique to deploy
models at new site where data distribution may be different from the original
training set. To achieve equivalent performance on new data, transfer learning
uses models pre-trained on datasets from previous hospitals to re-train the model
on new data. Ghafoorian et al. conducted experiments on transfer learning on
brain lesion segmentation tasks; and demonstrated that, without transfer learning,
the model completely failed on new data with the same follow-up patients and when
images were acquired with different acquisition protocols. With transfer learning
on a small set of new training examples, the model substantially outperformed a
model trained from scratch with the same size of training data [88]. The authors
also observed as the new training data becomes available, fine-tuning can be done
from the last full-connected layer to the last few convolutional layers.
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Transfer learning, however, can suffer from catastrophic forgetting issues, where the
knowledge about the old task may not be maintained when adapting parameters to
a new dataset or task. To avoid this pitfall and enable continual learning [89],
several approaches were proposed in the realm of brain segmentation. Garderen
et al. applied a regularization called elastic weight consolidation (EWC) during
transfer learning [90]. It penalizes large changes in model parameters weighted
based on their importance to the old dataset. Research on segmenting low- and
high-grade gliomas showed that EWC improved performance on the old domain
after transfer learning on the new domain. Conversely, it also restricted the
adaptation capacity to the new domain. Karani et al. suggested that learning
batch normalization parameters for each scanner and sharing the convolutional
filters between all scanners addressed the distribution shift among scanners [91].
The experiment showed this strategy can be adapted to new scanners or protocols
with only a few (≈ 4) labelled images and without degrading performance on the
previous scanners.
• Learning under data privacy constraint
Training models on data from multiple sites can improve model generalization.
However, due to data privacy and regulation issues, data is usually retained within
host hospital servers, and is not easily shared. Data privacy protection methods
can range from data anonymization, obfuscation (modifying data with noise to
provide protection, e.g.: differential privacy) [92], to federated learning (sharing
model parameters rather than raw data) and learning over encrypted data [93].
Federated learning is a private distributed and decentralized machine learning
method that trains the shared model locally with private data without exchanging
the raw patient data [94, 95]. Sheller et al. demonstrated federated learning on the
clinically-acquired BraTS data for institution-level segmentation tasks [96]. Their
study showed that the performance of federated semantic segmentation models
(Dice=0.852) was similar to that of models trained by sharing data (Dice=0.862),
and outperformed two alternative collaborative learning methods.
2.2.2. Handling different levels of annotation quality
Machine and deep learning models can be trained with varying levels of supervision.
Fully annotated ground truth labels for medical imaging data are expensive and
relatively scarce; however, images with weaker levels of annotation such as bounding
box annotations or image level annotations are relatively easier to acquire. Figure 5
shows the different levels of supervision for training a tumor segmentation model. A fully
supervised system would require manually annotated tumor segmentation regions (pixel-
wise labeling). Weaker levels of annotation can vary from bounding box annotations
of tumor region or image-level labels indicating whether a tumor is present (semi-
supervised learning), or no labels at all (unsupervised learning). For detailed description
of semi-supervised medical image analysis techniques, we refer the interested readers to
Cheplygina et al. [97].
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Figure 5. Different levels of supervision for a tumor segmentation task. Fully
supervised learning uses pixel-level annotations, whereas unsupervised learning does
not rely upon labels. Semi-supervised learning uses weak supervision varying from
bounding box annotations to just image-level labels.
Conventional machine learning methods have been deployed to learn from sparsely
annotated data. Azmi et al. [98] used stationary wavelet transform, edge features, and
fractal features in a semi-supervised framework with an ensemble of three algorithms
for segmenting brain tissues. Their approach achieved a higher accuracy and precision
than fully-supervised approaches, and they noted that supervised methods such as
k-nearest neighbor (KNN), SVM, and Bayesian classifiers were not able to perform
well with limited data. Blessy et al. [99] proposed an unsupervised approach for
MRI brain tumor segmentation based on optimal fuzzy clustering. They evaluated
their approach on MRI scans of 150 patients with low grade gliomas from the BraTS
dataset and outperformed four other clustering-based methods. Grande-Barreto et
al. [100] used priors about the brain structure and features extracted from the 3D gray
level co-occurence matrix (GLCM) for segmenting brain tissue, and observed superior
performance when evaluated on synthetic brain MR scans as compared to other state-
of-the-art unsupervised approaches.
More recently, there have been several deep learning-based semi-supervised and
unsupervised approaches applied to brain MR images. Chen et al. [101] trained
variational autoencoder [102] and adversarial autoencoder [103] models to learn the
latent space representation of healthy brains and introduced a representation consistency
constraint in the latent space, leading to a better lesion detection accuracy. Alex et
al. [104] proposed using stacked denoising autoencoders (DAE) [105] for segmenting
high grade gliomas, transfer learning for segmenting low grade gliomas, and a single layer
DAE for constructing error maps to improve lesion detection performance. Similarly,
Enguehard et al. [106] proposed a semi-supervised algorithm for infant brain MRI tissue
segmentation based on deep embedded clustering, and demonstrated the robustness of
their proposed approach by using the same network, optimizer, and learning rate for
two additional natural image classification tasks and achieving superior performance to
state-of-the-art semi-supervised methods. Dalca et al. [107] proposed a probabilistic
model and a novel loss function for unsupervised segmentation of brain MRI, and built
Applying Artificial Intelligence to Glioma Imaging: Advances and Challenges 13
upon the recent advances in deep learning-based registration methods to jointly estimate
the atlas deformation and the image intensity statistics, allowing them to train a deep
model on a new dataset without any manually annotated images.
In scenarios with multiple granularities of annotated ground truth, a mixed
supervision training approach can be adopted in order to utilize all the available
annotations. Zheng et al. [108] proposed a multi-atlas label fusion based method to
segment the hippocampus in brain MR images by integrating random forest classification
models with semi-supervised label propagation. Baur et al. [109] trained an autoencoder
to learn the representation of healthy brain scans, and then used it to detect and segment
anomalies in unlabeled scans. A U-Net [78] was then trained for supervised segmentation
with images paired with their labeled ground-truth data and unseen images paired with
the autoencoder output, thereby combining unsupervised and supervised techniques.
Mlynarski et al. [110] extended this architecture [78] by jointly performing classification
and segmentation, and utilized weakly annotated and fully annotated data to train a
deep model for tumor segmentation from brain MRI scans.
2.3. Clinical deployment
In this section, we describe approaches which address the main challenges to
translating the advances in machine and deep learning into clinical deployment: namely,
standardized evaluation metrics and model interpretability.
2.3.1. Standardized model evaluation
The existing literature reports the performances of AI models using a wide range of
evaluating metrics, e.g., accuracy, sensitivity, specificity, area under the curve (AUC),
and F1 scores for classification tasks, overlap-based measures such as the Dice score
coefficient and the intersection over union measure (also known as the Jaccard index)
for segmentation tasks. Table 1 summarizes the evaluation metrics used in the literature.
The metrics variability can lead to models being evaluated based on the reported best
metric, making horizontal comparisons among the models a difficult task. It is therefore
necessary to have a standardized set of evaluation metrics to provide a uniform platform
for comparison of different machine and deep learning models. One possible approach
to deal with this would be to report the model performance using all the conventional
evaluation metrics, thereby allowing for assessing the performance of newer models with
respect to the established benchmarks [119].
Moreover, high values for a reported metric of a model do not necessarily translate
into superior clinical performance, mainly due to the fact that individual metrics don’t
capture all the desirable properties for a model [120]. For example, a viable model needs
to be accurate, fast, and relatively small; invariably, there are trade-offs between model
performance, generalizability, and interpretability.
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Table 1. List of deep learning model architectures and evaluation metrics used in
glioma imaging.
Task Model architecture Evaluation metrics
Classification VGG16 [111] Accuracy [111, 112, 113, 114]
2D [112, 111] and 3D ResNet [113] Sensitivity or recall [111, 113, 114]
CNN+LSTMa [115] Specificity [114]
3D CNN with gated multimodal unit [114] Precision or PPVb [111, 113, 114, 115]
F1 score [111, 113, 115]
AUCc [113, 115]
Segmentation 2D [48, 91, 96, 110] and 3D U-Net [86, 90] Dice score [48, 86, 88, 90, 91, 96, 110, 116, 117]
Fully convolutional network [88] Specificity [117]
Densely connected CNN [116] Sensitivity [86, 117]
TwoPathCNN [117] Precision [86]
False positive rate [48, 86]
False negative rate [48]
Synthesis GAN [45, 48, 49, 50, 51, 52, 53, 118] MSEd [50, 118]
MAEe [45, 48]
PSNRf [45, 48, 49, 50, 51, 118]
SSIMg [49, 50, 51, 52, 53, 118]
aLSTM: long short-term memory; bPPV: positive predictive value; cAUC: Area under the receiver
operating characteristics; dMSE: mean squared error; eMAE: mean absolute error; fPSNR: peak
signal-to-noise ratio; gSSIM: structural similarity index
2.3.2. Model Interpretability
Compared to simple statistical models such as linear models, most machine and
deep learning approaches suffer from the notorious problem of using opaque models
(black-box models) rather than transparent ones (white-box models). Even though the
model parameters and architecture are known, tracing the relationship between input-
output pairs is a difficult challenge. This is partially due to the large number of model
parameters; deep neural networks usually have millions of parameters (for example,
the popular VGG16 architecture has over 138 million parameters). Furthermore, there
are complex representations in high-dimensional space, and multi-layered non-linear
mappings from input space to output predictions. In machine and deep learning
literature, this challenge is referred to as the model interpretability or explainable AI
(XAI) problem, i.e., to open the black box models and reveal how the model makes the
predictions in terms that human users can understand [121].
Model interpretability is especially important in deploying AI techniques in clinical
settings. With a black-box model, the clinical users will only receive a prediction without
an explanation or justification. Thus, it is difficult for clinical users to trust such models,
adopt the model results as part of the formal and legal medical report, and learn from
models to improve their expertise. XAI is therefore regarded as one of the “missing
pieces” of AI in medicine [27, 122]. Although XAI is still an emerging field, there have
been some recent attempts to explain AI models on glioma imaging predictive tasks. In
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the subsequent sections, we introduce different approaches to explaining AI decisions to
clinical users, and summarize progress in applying XAI to glioma imaging tasks.
Explanations of the model’s prediction can be produced at different levels and
using different approaches. Local and global explanations are explanations at
different levels of granularity [123]. Local explanations explain how the model makes
the decision for one data point, usually when doctors are seeking explanations for a
particular clinical case, and global explanations explain how the model makes decisions
in general. Similarly, post-hoc and intrinsic (ante-hoc) explanations are two
distinct approaches to generate explanations [124]. Post-hoc explanation builds a proxy
explanatory model to explain the original black-box model. It is especially suitable in
explaining black-box models that are already put in use or those that use a specific
architecture. In contrast, for models that have not been put into practice or do not
have their architecture specified, we can build intrinsic (ante-hoc) explainable models
that both perform predictive tasks and explain the predictions.
A prerequisite of useful XAI is that the generated explanations need to be easily
understandable by clinical users. Creating explanations for clinical end-users is more
challenging since they usually do not have prior knowledge in ML or AI models. Jin et
al. surveyed the existing XAI literature and identified three explanatory forms that are
accessible to non-technical users [125]:
• Explaining using feature attributes to identify the most important features that
have the highest influence on the predicted outcome.
• Explaining using examples to show users instances that the model regards to be
similar to the query image, or are typical to the prediction.
• Explaining using decision rules to show users the decision flows that the model
follows.
All the features, examples and rules should be presented in user-understandable forms.
As such, we organize the following summary of XAI advances on glioma imaging
according to the aforementioned clinical-user-friendly explanatory forms.
Applying XAI methods to glioma imaging tasks is still at a nascent stage. The
purposes of applying XAI in glioma imaging include model quality assessment, resolving
users’ perceived anomalies, gaining users’ trust, improving physician expertise and
assisting in scientific discovery (such as identifying imaging biomarkers).
(i) Explaining using feature attributes
Feature attribution is the most common form of explanation in the XAI literature.
In an interview with clinicians about their requirements for XAI, doctors expressed
the need to understand the important features that align with accepted medical
paradigms [126]. Features are shown with their types of pathological changes,
their importance scores, and their locations on the image. Such information
can be presented in forms of text descriptions, color maps (or saliency maps)
or segmentation maps overlaid unto input images. Next, we introduce three
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approaches to generate post-hoc explanations based on “activation”, “gradient”,
and “input perturbation”.
(a) Activation-based methods
For deep learning-based image tasks using convolutional neural networks
(CNNs), a usual approach to reveal what the network has learned is to utilize
the information from the internal activation maps. For example, Ahmad et
al. applied a class activation map (CAM) method on 2D ResNet CNN to
predict IDH mutation status in high-grade gliomas [111]. They demonstrated
that the generated saliency maps correspond to the tumor area in most IDH1
mutant cases, while in most IDH1 wild-type cases, the peri-tumoral edema
is also involved. The CAM method reveals where the intermediate CNN
layer is “looking at” to make the prediction. It has become popular in the
computer vision literature since 2015 [127]. Given an input image, it acquires
the internal activation maps in a particular layer, and aggregates them using
their respective weights from the global average pooling layer to generate a
color map with the same size as the input image. Since the CAM method
gives explanations on a single image, it is a local explanation method.
“Attention mechanism” is another approach to reveal the significant features in
input data. It learns to assign “importance weights” to activation maps (in the
case of CNN) or hidden states (in the case of recurrent neural network). The
weighted sum of the attention map can be overlaid on input data to show how
the model attends to important regions in input data. For instance, Choi et al.
built an attention-based long short-term memory (LSTM) neural network to
identify IDH status from dynamic susceptibility contrast (DSC) perfusion MRI
time-series data [128]. The model “paid more attention” to the combination
of the end of the pre-contrast baseline, up/downslopes of signal drops, and/or
post-bolus plateaus for the curves used to predict IDH genotype.
(b) Gradient-based methods
Since gradient reflects the magnitude of output change in accordance with
input change, it can provide users with clues of the important input features
for the results. For example, to check if the model’s predictions align with
accepted medical knowledge, Meier et al. applied Grad-CAM and guided-
backpropagation on 3D MRI CNN for classification of brain tumor grades [113].
By visually inspecting some of the saliency maps that do not contain the tumor
regions, users may conclude that the prediction may not be reliable. Similarly,
Huang et al. also applied 3D-based Grad-CAM on classifying high- vs. low-
grade glioma to compare model performances on synthesized MR modalities
with ground-truth complete modalities [118]. The resultant saliency map
highlighted the tumor regions as the important image features that contribute
to the tumor grading.
Both grad-CAM and guided-backpropagation methods depend on the gradient
of the output with respect to the input to compute how the change of input will
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influence the change of output. Specifically, Grad-CAM, or gradient-weighted
class activation map, can be regarded as a modification of the earlier CAM
methods. Both utilize the weighted combination of activation maps to produce
the saliency map; and the difference is in how they apply weighting to the
activation maps. Unlike CAM that uses weights from global average pooling
layer, grad-CAM takes weights from the gradients of the target class output
with respect to the activation maps. Thus, it aggregates information both
from activation maps and gradients, and can create a more localized saliency
map than CAM [129]. Guided-backpropagation adds an additional guidance
signal (gradient from top layer) to usual backpropagation which computes
gradients from the bottom layer. This can create clearer and less noisy saliency
maps [130].
(c) Perturbation-based methods
The above-mentioned methods apply to cases where we have access to
model parameters, activations, and architecture information. Sometimes
such knowledge is unknown to its model users, due to safety, privacy, or
intellectual property issues. Perturbation-based method is used to reveal
how the model makes predictions by probing the model with different inputs
and analyzing the input-output pairs. It constitutes a post-hoc method
and is model-agnostic (i.e., can be applied to any black-box models). In
a work to segment gliomas from MRI, Pereira et al. applied the local
interpretable model-agnostic explanations (LIME) [131] to the ML model for
local interpretability [132]. Their ML model is a restricted Boltzmann machine
for unsupervised representation learning, and a random forest classifier for
voxel-level segmentation. They perturbed the features to generate synthetic
neighbours that are close to the original data in the feature representation
space, and also acquired the predicted output of these neighbours. With
the input-output pairs, they trained a ridge regressor and used its weights
as the importance-measure of each feature, shown as saliency maps on the
MRI images. The saliency maps showed that FLAIR sequences were the most
important for segmenting the complete tumor while segmentation of edema was
mainly based on FLAIR and T1c sequence. They also showed that the T2 and
T1c sequences were important for segmenting necrosis, and T1c was important
in segmenting the enhancing rim region. These findings correspond well with
accepted radiologic principles; thus, confirming that the model learned the
correct relations in the data.
(ii) Explaining using examples
Compared to feature attribution, explaining using examples can provide more
contextual information about how the model learned, and is more intuitive as
clinicians are used to learning from examples. In a user study with ICU clinicians,
the researchers observed the example-based explanations facilitated clinicians’
analogical reasoning [133]. Another study involving pathologists showed that
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examples with similar visual appearance and different diagnoses can help physicians
broaden their differential diagnosis [134].
For example-based explanations applied to glioma imaging tasks, Chang et al.
identified the prototypical images to predict IDH mutation, 1p/19q codeletion and
MGMT methylation status [112]. They built CNN models on 2D MRI slices from
the TCIA dataset and identified the prototypical images that caused the most
activation of the units in the final fully-connected decision layer. The typical
images for IDH mutation demonstrated absent or minimal enhancement with well-
defined tumor margins in T1c, or central areas of cysts with FLAIR suppression.
Conversely, IDH wild-type tumors exhibit thick and irregular enhancement or thin,
irregular peripheral enhancement in T1c, and infiltrative patterns of edema on
FLAIR. Such prototypical images serve as global explanations of the model’s overall
prediction.
XAI evaluating metrics To evaluate interpretability methods, Doshi-Velez and
Kim proposed an evaluation framework at three levels: functionally-grounded evaluation
(using function as a proxy to measure interpretability), human-grounded evaluation
(evaluating with lay-person’s cognition and understanding), and domain expert-
grounded evaluation (evaluating the interpretability on domain-specific tasks) [121].
Current XAI techniques on glioma imaging have little to no evaluation. This is probably
due to the fact that the current XAI explorations are more focused on revealing the
model’s predictions and checking how well the learned model aligns with doctors prior
knowledge, rather than considering the practical challenges associated with the clinical
implementation of XAI. The research of clinical utility of XAI on glioma imaging is at
its inception and has many unsolved questions waiting to be explored.
3. Discussion
In this manuscript, we have summarized recent efforts toward increasing the clinical
utility of AI in neuro-oncology by addressing the current challenges in data collection,
model training and clinical deployment. The current research, however, focuses more
on novel algorithm design, rather than actually applying them in real-world patient-
care settings. As the performance of machine and deep learning models improves and
the challenges enumerated are addressed, we foresee greater interest in translational
research that aims to apply novel technologies to the bedside. To this end, we next
highlight further advances which are necessary for the full implementation of AI in
glioma imaging; to develop clinical decision support systems (CDSS) and facilitate the
personalization of care.
Clinical workflow integration Implementing AI in patient-care settings requires
the AI technologies to be integrated into the existing clinical workflow. Several steps
are needed to achieve clinical workflow integration: First, before the design of an AI
system, clinical requirements should be ascertained and a “needs assessment” should be
performed. Furthermore, a user-centric design approach should be applied during the
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AI system design and iteration. This step solicits clinician feedback in the design of
user-friendly interfaces and reduces the cognitive-load for physicians while supporting
their clinical tasks. Moreover, the implemented system needs to take advantage of
newly acquired patient data using online machine learning, to continually improve the
performance of the predictive models. The systems can also use “adaptive learning”
to adapt to user’s behaviours and preferences, i.e. “hybrid learning” or “human-in-the-
loop” machine learning [135].
Achieving the above steps will need close collaboration between physicians, AI
experts and human-computer interaction developers.
Clinical evaluation Appropriately evaluating the functionality of AI systems is
necessary prior to its clinical implementation. We can make an analogy of evaluating
the clinical utility of AI to the conventional four-phase clinical trials for medications or
medical devices:
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Figure 6. The four phases of evaluating the clinical utility of AI in glioma imaging.
• Phase I is to primarily test the performance of the AI model. This phase
only involves the AI model and test data, and does not involve human users.
Most current AI system-evaluation is at this stage and tests AI performance on
unseen data with model-based evaluation metrics, such as classification accuracy,
sensitivity, specificity, AUC (area under the receiver operating characteristics),
or mean squared error, as listed in Table 1. For example, Li et al. created a
clinical application called GliomaPredict that used an unsupervised ML principle
component analysis (PCA) to classify patients with gliomas into 6 subtypes
according to their glioma transcriptomic profiles [136]. It generated a visual
representation of the analyses, quantified the confidence of the underlying subtype
assessment, and presented results as a printable PDF file. The application was
evaluated based on the model performance on new patient data and yielded 75-
96% of prediction accuracy.
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• Phase II involves clinical users in experimental settings using simulated tasks
(usually on held-out test data) rather than in real clinical settings. The evaluation
metrics are usually model-based metrics. Earlier works focused on the head-to-head
comparison of doctors’ performance with AI models, mainly to indicate that AI
matches doctor-level performance [137, 138]. More recently, studies have involved
doctor+AI as a third arm in the AI vs. doctor comparisons. For example, Bien
et al. found that physicians who used AI predictions had significantly improved
specificity in identifying anterior cruciate ligament tears from knee MRI compared
to doctors who didn’t have these predictions [139]. This evaluation trend reflects
a paradigm shift from AI replacing doctors, to AI augmenting doctors.
• Phase III involves clinical users in real-world settings using randomized controlled
trials. In addition to using model-based evaluation metrics, other clinical outcome
metrics can be evaluated, such as patients’ outcome, physicians’ performance
or efficiency, clinical usability and health economics. So far, very few studies
have entered this phase. In a randomised controlled trial, Wang et al. enrolled
a total of 1,058 patient to evaluate an AI-assisted polyp detection system
during colonoscopy [28]. Compared with standard colonoscopy, the AI-assisted
colonoscopy increased the adenoma detection rates by 50%, from 20% to 30%.
• Phase IV is for post-marketing software support and surveillance. This phase will
follow the launch and clinical implementation of AI systems.
4. Conclusions
Because of their significant clinical burden, gliomas are one of the most highly studied
cancers. Machine and deep learning techniques have the potential to increase the clinical
yield of non-invasive imaging studies, from segmenting tumors for quantitative measures,
to identifying molecular subtypes and grades; from evaluating treatment response to
predicting patient prognosis. Despite recent advances, AI technologies have not yet
become fully functional in the management of patients with gliomas. In our review,
we have summarized recent efforts to address practical challenges in applying AI to
clinical settings. Multiple data and annotation collection efforts, together with data
imputation and synthesize methods, were presented. We also discussed different model
training strategies, and methods of learning under limited supervision. Furthermore, we
have presented various standardized model evaluation metrics and model interpretability
methods. Finally, we have proposed necessary future steps towards workflow integration
and provided a framework for evaluating the clinical utility of AI-assisted systems. Due
to the scope of the paper, we have focused on the technical barriers to implementation;
and, approaches to overcome these challenges. Specifically, we have not discussed non-
technical, financial and legal issues which will, no doubt, need to be considered in the
future. Ultimately, the full implementation of AI-based tools in neuro-oncology will
significantly improve the care of patients with gliomas.
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